GGrantIndex
Sort

39,280 grants matching leukemia

Targeting aberrant epigenetics by nanomedicine

$327,444
Shujun Liu · University Of Minnesota · R01 · FY2013 · CA

Project 1: HDAC inhibition and GVHD

$327,440
Pavan Reddy · Icahn School Of Medicine At Mount Sinai · P01 · FY2020 · CA

Autologous CD19 Targeted 19-28z+ Tcells for the Treatment of Relapsed Diffuse Large B cell Lymphoma in Transplant Ineligible Elderly Patients

$327,436
Renier Joseph Brentjens · Sloan-Kettering Inst Can Research · P50 · FY2018 · CA

Gene-Engineered Stem Cell Memory T-Cells With Anti-HIV Chimeric Antigen Receptors

$327,432
Masakazu Kamata · University Of Alabama At Birmingham · R01 · FY2019 · AI

Defining the Role of MafA in Islet Beta Cells

$327,425
Roland W Stein · Vanderbilt University · R01 · FY2013 · DK

Heme trafficking and its impact on systemic iron homeostasis

$327,425
Janis L Abkowitz · University Of Washington · R01 · FY2013 · DK

DEVELOPMENT OF ANTICANCER 1, 2-BIS(SULFONYL) HYDRAZINES

$327,409
Yale University · R01 · FY2002 · CA

Cell Cycle Regulation and Leukemogenesis by CBFb-SMMHC

$327,409
Johns Hopkins University · R01 · FY2005 · CA

DEVELOPMENT OF ANTICANCER 1, 2-BIS(SULFONYL) HYDRAZINES

$327,409
Yale University · R01 · FY2003 · CA

Cell Cycle Regulation and Leukemogenesis by CBFb-SMMHC

$327,409
Johns Hopkins University · R01 · FY2003 · CA

Cell Cycle Regulation and Leukemogenesis by CBFb-SMMHC

$327,409
Johns Hopkins University · R01 · FY2004 · CA

DEVELOPMENT OF ANTICANCER 1, 2-BIS(SULFONYL) HYDRAZINES

$327,409
Yale University · R01 · FY2004 · CA

RNA Tumor Virus-Hematopoietic cell Interaction

$327,350
Naomi Rosenberg · Tufts University Boston · R01 · FY2006 · CA

The chromatin response in mammalian double strand break repair

$327,342
Ralph Scully · Beth Israel Deaconess Medical Center · R01 · FY2012 · GM

The chromatin response in mammalian double strand break repair

$327,342
Ralph Scully · Beth Israel Deaconess Medical Center · R01 · FY2014 · GM

Pharmacogenomics of cytosine arabinoside (Ara-C) and acute myelogenous leukemia

$327,333
Richard M Weinshilboum · Mayo Clinic Rochester · R01 · FY2011 · CA

Characterization of a T cell dysfunctional state induced in mice with AML

$327,332
Justin P. Kline · University Of Chicago · R01 · FY2012 · CA

Role of autophagy in normal and transformed hematopoietic stem cells

$327,332
Emmanuelle Passegue · University Of California, San Francisco · R01 · FY2014 · CA

Genomic biomarkers for cutaneous T-cell Lymphoma

$327,323
Megan S. Lim · Sloan-Kettering Inst Can Research · R01 · FY2024 · CA

Data Compilation Core

$327,307
Stephen L George · Univ Of North Carolina Chapel Hill · P01 · FY2013 · CA

Improving Biopsies using Magnetic Nanoparticles

$327,296
Edward R Flynn · Senior Scientific · R44 · FY2009 · CA

DISCOVERY OF FIRST-IN-CLASS NSD2 DEGRADERS FOR CANCER THERAPY

$327,284
Lindsey Ingerman James · Univ Of North Carolina Chapel Hill · R01 · FY2023 · CA

Project 5: Transplant Conditioning for MDS and AML with Biological Agents

$327,278
Judith Anne Shizuru · Stanford University · P01 · FY2021 · CA

Project 5: Transplant Conditioning for MDS and AML with Biological Agents

$327,278
Judith Anne Shizuru · Stanford University · P01 · FY2023 · CA

CD 74 Directed Immunotherapy for B Cell Malignancies

$327,262
John P Leonard · Weill Medical Coll Of Cornell Univ · R21 · FY2007 · CA